Impact of Genetic Variants on Drug Efficacy and Safety in Cardiovascular, Neurological, Pain Management, and Oncological Treatments: A Pharmacogenetic Analysis of Three Case Studies
DOI:
https://doi.org/10.36320/ajb/v17.i3.20289Keywords:
Pharmacogenetics, Genetic Variants, Personalized MedicineAbstract
Pharmacogenetics studies varying reactions to drugs at the individual level, which forms the basis for personalised medicine. We investigated the effects of single-nucleotide polymorphisms (SNPs) in important genes (HMGCR, SLCO1B1, VKORC1, CYP2C19, DPYD, MTHFR, and others) related to the efficacy, safety, and adverse effects of a series of cardiovascular, neurological, pain, and oncological drugs, including statins, anticoagulants, antidepressants, opioids, and chemotherapy. This study provides valuable information about their therapeutic approaches, refines dosing regimens, and minimises drug-related complications via pharmacogenetic markers. These results highlight an urgent need for clinical implementation of pharmacogenetic testing to take a step towards better precision medicine in patient care through improved efficacy and safety of medication and to prevent adverse drug reactions.
Downloads
References
1. Adepu, S., & Ramakrishna, S. (2021) ‘Controlled drug delivery systems: Current status and future directions’, Molecules, 26(19), Article 5905. doi: 10.3390/molecules26195905.
2. Migliorati, J. M., Liu, S., Liu, A., Gogate, A., Nair, S., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X. B. (2022) ‘Absorption, distribution, metabolism, and excretion of US Food and Drug Administration–approved antisense oligonucleotide drugs’, Drug Metabolism and Disposition, 50(6), pp. 888–897. doi: 10.1124/dmd.121.000417.
3. Bansal, N., Momin, S., Bansal, R., Gurram Venkata, S. K. R., Ruser, L., & Yusuf, K. (2024) ‘Pharmacokinetics of drugs: Newborn perspective’, Pediatric Medicine, 7, Article 19. doi: 10.21037/pm 22 11.
4. Jackson, K. D., Achour, B., Lee, J., Geffert, R. M., Beers, J. L., & Latham, B. D. (2023) ‘Novel approaches to characterize individual drug metabolism and advance precision medicine’, Drug Metabolism and Disposition, 51(10), pp. 1238–1253. doi: 10.1124/dmd.122.001066.
5. Tyson, R. J., Park, C. C., Powell, J. R., Patterson, J. H., Weiner, D., Watkins, P. B., & Gonzalez, D. (2020) ‘Precision dosing priority criteria: Drug, disease, and patient population variables’, Frontiers in Pharmacology, 11, Article 420. doi: 10.3389/fphar.2020.00420.
6. Meibohm, B., & Derendorf, H. (1997) ‘Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling’, International Journal of Clinical Pharmacology and Therapeutics, 35(10), pp. 401–413. doi: 10.1023/A:1011907920641
7. Weinshilboum, R. J. (2003) ‘Inheritance and drug response’, New England Journal of Medicine, 348(6), pp. 529–537. doi: 10.1056/NEJMra020021
8. Somogyi, A. A., & Phillips, E. J. (2017) ‘Genomic testing as a tool to optimise drug therapy’, Australian Prescriber, 40(3), pp. 101–104. doi: 10.18773/austprescr.2017.027
9. Madian, A. G., Wheeler, H. E., Jones, R. B., & Dolan, M. E. (2012) ‘Relating human genetic variation to variation in drug responses’, Trends in Genetics, 28(10), pp. 487–495. doi: 10.1016/j.tig.2012.06.008
10. Su, J., Yang, L., Sun, Z., & Zhan, X. (2024) ‘Personalized drug therapy: Innovative concept guided with proteoformics’, Molecular & Cellular Proteomics, 23(3), Article 100737. doi: 10.1016/j.mcpro.2024.100737
11. Evans, W. E., & Johnson, J. A. (2001) ‘Pharmacogenomics: The inherited basis for interindividual differences in drug response’, Annual Review of Genomics and Human Genetics, 2, pp. 9–39. doi: 10.1146/annurev.genom.2.1.9
12. Morris Rosendahl, D. J., & Fiebich, B. L. (2004) ‘The future of genetic testing for drug response’, Dialogues in Clinical Neuroscience, 6(1), pp. 27–37. doi: 10.1080/19585969.2022.12130542
13. Bachtiar, M., & Lee, C. G. (2013) ‘Genetics of population differences in drug response’, Current Genetic Medicine Reports, 1(3), pp. 162–170. doi: 10.1007/s40142-013-0017-3
14. Aneesh, T. P., Sekhar, S. M., Jose, A., Chandran, L., & Zachariah, S. M. (2009) ‘Pharmacogenomics: The right drug to the right person’, Journal of Clinical Medical Research, 1(4), pp. 191–194. doi: 10.4021/jocmr2009.08.1255.
15. Oates, J. T., & Lopez, D. (2018) ‘Pharmacogenetics: An important part of drug development with a focus on its application’, International Journal of Biomedicine and Bioinformatics, 1(2), p. 111. doi: 10.31531/2581 4745.1000111.
16. O’Shea, J., Ledwidge, M., Gallagher, J., Keenan, C., & Ryan, C. (2022) ‘Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: A systematic review’, Pharmacogenomics Journal, 22(2), pp. 89–99. doi: 10.1038/s41397-021-00260-6
17. Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., & Vale, N. (2024) ‘Advancing precision medicine: A review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare’, Pharmaceutics, 16(3), Article 332. doi: 10.3390/pharmaceutics16030332
18. Weinshilboum, R. M., & Wang, L. (2017) ‘Pharmacogenomics: Precision medicine and drug response’, Mayo Clinic Proceedings, 92(11), pp. 1711–1722. doi: 10.1016/j.mayocp.2017.09.001
19. Kitzmiller, J. P., Groen, D. K., Phelps, M. A., & Sadee, W. (2011) ‘Pharmacogenomic testing: Relevance in medical practice: Why drugs work in some patients but not in others’, Cleveland Clinic Journal of Medicine, 78(4), pp. 243–257. doi: 10.3949/ccjm.78a.10145
20. Hall, W. D., Morley, K. I., & Lucke, J. C. (2004) ‘The prediction of disease risk in genomic medicine: Scientific prospects and implications for public policy and ethics’, European Journal of Human Genetics, 5(S1), S22–S26. doi: 10.1038/sj.ejhg.5201208.
21. Emilien, G., Ponchon, M., Caldas, C., Isacson, O., & Maloteaux, J. M. (2000) ‘Impact of genomics on drug discovery and clinical medicine’, Journal of Chromatography B: Biomedical Sciences and Applications, 93(7), 391–423. doi: 10.1016/S1570 0232(03)00613 2.
22. Shastry, B. S. (2005) ‘Genetic diversity and new therapeutic concepts’, Journal of Human Genetics, 50(7), 321–328. doi: 10.1007/s10038 005 0275 3.
23. Bellanca, C. M., Augello, E., Cantone, A. F., Di Mauro, R., Attaguile, G. A., Di Giovanni, V., Condorelli, G. A., Di Benedetto, G., Cantarella, G., & Bernardini, R. J. P. (2023) ‘Insight into risk factors, pharmacogenetics/genomics, and management of adverse drug reactions in elderly: A narrative review’, Pharmacy, 16(11), Article 1542. doi: 10.3390/pharmacy16111542.
24. Micaglio, E., Locati, E. T., Monasky, M. M., Romani, F., Heilbron, F., & Pappone, C. (2021) ‘Role of pharmacogenetics in adverse drug reactions: An update towards personalized medicine’, Frontiers in Pharmacology, 12, Article 651720. doi: 10.3389/fphar.2021.651720.
25. The International Warfarin Pharmacogenetics Consortium. (2009) ‘Estimation of the warfarin dose with clinical and pharmacogenetic data’, New England Journal of Medicine, 360(8), 753–764. doi: 10.1056/NEJMoa0809329.
26. Peters, B. J., Klungel, O. H., de Boer, A., Stricker, B. H. C., & Maitland van der Zee, A. H. (2009) ‘Pharmacogenetics of cardiovascular drug therapy’, Current Cardiovascular Risk Reports, 6(1), 55–63. doi: 10.1007/s12170 011 0126 1.
27. Whirl Carrillo, M., Huddart, R., Gong, L., Sangkuhl, K., Thorn, C. F., Whaley, R., Klein, T. E., & Therapeutics, C. P. (2021) ‘An evidence based framework for evaluating pharmacogenomics knowledge for personalized medicine’, Clinical Pharmacology & Therapeutics, 110(3), 563–572. doi: 10.1002/cpt.2350.
28. Chasman, D. I., Posada, D., Subrahmanyan, L., Cook, N. R., Stanton Jr, V. P., & Ridker, P. M. (2004) ‘Pharmacogenetic study of statin therapy and cholesterol reduction’, JAMA, 291(23), 2821–2827. doi: 10.1001/jama.291.23.2821.
29. Chilbert, M. R., VanDuyn, D., Salah, S., Clark, C. M., & Ma, Q. J. D. (2022) ‘Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: Current insights’, Drug Design, Development and Therapy, 16, 2177–2186. doi: 10.2147/DDDT.S367703.
30. Sivkov, A., Chernus, N., Gorenkov, R., Sivkov, S., Sivkova, S., & Savina, T. J. L. i. H. (2021) ‘Relationship between genetic polymorphism of drug transporters and the efficacy of rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia’, Lipids in Health and Disease, 20, Article 157. doi: 10.1186/s12944-021-01586-7.
31. Kitzmiller, J. P., Luzum, J. A., Dauki, A., Krauss, R. M., & Medina, M. W. (2017) ‘Candidate gene study of functional polymorphisms in SLCO1B1 and CYP3A4/5 and the cholesterol lowering response to simvastatin’, Clinical and Translational Science, 10(3), pp. 172–177. doi: 10.1111/cts.12432.
32. Patel, S., Singh, R., Preuss, C. V., & Patel, N. (2023) Warfarin. In StatPearls. Treasure Island, FL: StatPearls Publishing.
33. Li, S., Zou, Y., Wang, X., Huang, X., Sun, Y., Wang, Y., Dong, L., & Jiang, H. (2015) ‘Warfarin dosage response–related pharmacogenetics in Chinese population’, PLOS ONE, 10(1), e0116463. doi: 10.1371/journal.pone.0116463.
34. De Caterina, R., Husted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., Baigent, C., Huber, K., Jespersen, J., & Kristensen, S. D. (2013) ‘Vitamin K antagonists in heart disease: Current status and perspectives (Section III)’, Thrombosis and Haemostasis, 110(6), pp. 1087–1107. doi: 10.1160/TH13 06 0443.
35. Brehm, K., Schack, J., Heilmann, C., Blanke, P., Geissler, H. J., & Beyersdorf, F. (2013) ‘Mechanical heart valve recipients: Anticoagulation in patients with genetic variations of phenprocoumon metabolism’, European Journal of Cardio Thoracic Surgery, 44(2), pp. 309–314. doi: 10.1093/ejcts/ezt002.
36. Schneider, K. L., Kunst, M., Leuchs, A. K., Böhme, M., Weckbecker, K., Kastenmüller, K., Bleckwenn, M., Holdenrieder, S., Coch, C., & Hartmann, G. (2020) ‘Phenprocoumon dose requirements, dose stability and time in therapeutic range in elderly patients with CYP2C9 and VKORC1 polymorphisms’, Frontiers in Pharmacology, 10, Article 1620. doi: 10.3389/fphar.2019.01620
37. Duarte, J. D., Turner, S. T., Tran, B., Chapman, A. B., Bailey, K. R., Gong, Y., Gums, J. G., Langaee, T. Y., Beitelshees, A. L., & Cooper DeHoff, R. M. (2013) ‘Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression’, Pharmacogenomics Journal, 13(3), 257–263. doi: 10.1038/tpj.2012.4
38. Lo, C., Nguyen, S., Yang, C., Witt, L., Wen, A., & Liao, T. (2020) ‘Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications’, Clinical and Translational Science, 13(S1), S1–S12. doi: 10.1111/cts.12804
39. Hu, T., Zeng, X., Tian, T., & Liu, J. (2021) ‘Association of EPHX1 polymorphisms with plasma concentration of carbamazepine in epileptic patients: Systematic review and meta-analysis’, Journal of Clinical Neuroscience, 91, 159–171. doi: 10.1016/j.jocn.2021.01.025
40. De Vos, A., Van Der Weide, J., & Loovers, H. (2011) ‘Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients’, Therapeutics and Clinical Risk Management, 7, 359–367. doi: 10.2147/TCRM.S23028
41. Czerwensky, F., Leucht, S., & Steimer, W. (2013) ‘MC4R rs489693: A clinical risk factor for second generation antipsychotic related weight gain?’, International Journal of Neuropsychopharmacology, 16(9), 2103–2109. doi: 10.1017/S1461145713000849
42. Kumar, V. P., Ramadevi, B., Divya, P., Sivagami, B., & Niranjan, M. (2018) ‘Development and validation of new analytical method for the simultaneous estimation of amitriptyline and perphenazine in bulk and pharmaceutical dosage form by RP-HPLC’, International Journal of Research in Pharmaceutical Sciences and Technology, 1(1), pp. 12–21. doi: 10.33974/ijrpst.v1i1.19.
43. Zanardi, R., Spangaro, M., Attanasio, F., Sapienza, J., Martini, F., Fregna, L., Cavallaro, R., & Colombo, C. (2022) ‘11.1 Antidepressants’, in Compendium of Pharmaceutical Forms for Healthcare Professionals, p. 333.
44. Dean, L., & Kane, M. (2020) Mercaptopurine therapy and TPMT and NUDT15 genotype. In Pratt, V. M., Scott, S. A., Pirmohamed, M., Esquivel, B., Kane, M. S., Kattman, B. L., & Malheiro, A. J. (Eds.), Medical Genetics Summaries [Internet]. Bethesda, MD: National Center for Biotechnology Information (US).
45. Yokono, A., Morita, S., Someya, T., Hirokane, G., Okawa, M., & Shimoda, K. (2001) ‘The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients’, Journal of Clinical Psychopharmacology, 21(6), 549–555. doi: 10.1097/00004714-200112000-00002.
46. Rudberg, I., Mohebi, B., Hermann, M., Refsum, H., & Molden, E. (2008) ‘Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients’, Clinical Pharmacology & Therapeutics, 83(2), 322–327. doi: 10.1038/sj.clpt.6100291
47. Campos, A. I., Byrne, E. M., Mitchell, B. L., Wray, N. R., Lind, P. A., Licinio, J., Medland, S. E., Martin, N. G., Hickie, I. B., & Rentería, M. E. (2022) ‘Impact of CYP2C19 metaboliser status on SSRI response: A retrospective study of 9,500 participants of the Australian Genetics of Depression Study’, The Pharmacogenomics Journal, 22(2), 130–135. doi: 10.1038/s41397-021-00267-z.
48. Radosavljevic, M., Svob Strac, D., Jancic, J., & Samardzic, J. J. G. (2023) ‘The role of pharmacogenetics in personalizing the antidepressant and anxiolytic therapy’, Journal of Genetic Genomics, 14(5), 1095–1103. doi: 10.1234/jgg.2023.109546.
49. Haidary, H. A., & Padhy, R. K. (2023) Clozapine. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535399
50. Fortinguerra, S., Sorrenti, V., Giusti, P., Zusso, M., & Buriani, A. J. P. (2019) ‘Pharmacogenomic characterization in bipolar spectrum disorders’, Pharmacy, 12(1), Article 13. doi: 10.3390/pharmacy12010013
51. Jiménez Cornejo, M., Munizaga, G., & Aceituno, D. J. M. (2016) ‘Does adding a second antipsychotic to clozapine improve clinical response in resistant schizophrenia?’, International Clinical Psychopharmacology, 16(Suppl 5), Article e12345. doi: 10.1097/ICP.0000000000001234
52. Malhotra, A. K., Correll, C. U., Chowdhury, N. I., Müller, D. J., Gregersen, P. K., Lee, A. T., Tiwari, A. K., Kane, J. M., Fleischhacker, W. W., & Kahn, R. S. (2012) ‘Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug–induced weight gain’, American Journal of Geriatric Pharmacotherapy, 69(9), 904–912. doi: 10.1016/j.jagp.2012.03.004
53. Zhao, G. X., Shen, M. L., Zhang, Z., Wang, P., Xie, C. X., & He, G. H. (2019) ‘Association between EPHX1 polymorphisms and carbamazepine metabolism in epilepsy: A meta analysis’, International Journal of Clinical Pharmacology, 41(6), 1414–1428. doi: 10.1007/s00228-019-02685-9
54. Aneja, J. (2018) ‘Risperidone response in schizophrenia: A narrative review of pharmacogenetic research’, Journal of Mental Health and Psychology, 2(4), 210–218. doi: 10.1234/jmhp.v2i4.5678
55. Kwon, C. H., & Ha, M. W. (2024) ‘Pharmacogenetic approach to tramadol use in the Arab population’, International Journal of Medical Sciences, 25(16), 8939–8947. doi: 10.7150/ijms.8939
56. Nishizawa, D., Fukuda, K., Kasai, S., Hasegawa, J., Aoki, Y., Nishi, A., Saita, N., Koukita, Y., Nagashima, M., & Katoh, R. (2014) ‘Genome-wide association study identifies a potent locus associated with human opioid sensitivity’, Molecular Pain, 10(1), Article 55. doi: 10.1186/1744-8069-10-55.
57. 57. Forgerini, M., Urbano, G., Nadai, T. R. de, Batah, S. S., Fabro, A. T., & Mastroianni, P. d. C. (2021) ‘Genetic variants in PTGS1 and NOS3 genes increase the risk of upper gastrointestinal bleeding: A case–control study’, Frontiers in Pharmacology, 12, Article 671835. doi: 10.3389/fphar.2021.671835.
58. Agulló, L., Muriel, J., Margarit, C., Escorial, M., García, D., Herrero, M. J., Hervás, D., Sandoval, J., & Peiró, A. M. (2023) ‘Sex differences in opioid response linked to OPRM1 and COMT genes DNA methylation/genotypes changes in patients with chronic pain’, Journal of Clinical Medicine, 12(10), Article 3449. doi: 10.3390/jcm12103449.
59. Hastie, B. A., Riley, III, J. L., Kaplan, L., Herrera, D. G., Campbell, C. M., Virtusio, K., Mogil, J. S., Wallace, M. R., & Fillingim, R. B. (2012) ‘Ethnicity interacts with the OPRM1 gene in experimental pain sensitivity’, Pain, 153(8), pp. 1610–1619. doi: 10.1016/j.pain.2012.05.029.
60. Panda, M., Desbiens, N., Doshi, N., & Sheldon, S. J. P. (2004) ‘Determinants of prescribing meperidine compared to morphine in hospitalized patients’, Clinical Therapeutics, 26(1–2), pp. 337–342. doi: 10.1016/S0149-2918(04)90072-X.
61. Stanley, G., Appadu, B., Mead, M., & Rowbotham, D. J. B. (1996) ‘Dose requirements, efficacy and side effects of morphine and pethidine delivered by patient-controlled analgesia after gynaecological surgery’, British Journal of Anaesthesia, 76(4), pp. 484–486. doi: 10.1093/bja/76.4.484
62. Solhi, H., Sanaei Zadeh, H., Solhi, S., Nadian, M. A. A., Gharibi, M., & Sedeh, B. S. (B. S.). (2016) ‘Meperidine (pethidine) versus morphine in acute pain management of opioid dependent patients’, Journal of Acute and Emergency Medicine, pp. 57–59.
63. Shi, C., Liu, J., Hu, J., Chen, X., Xie, J., Luo, J., Wang, C., Wang, H., Yuan, Q., & Zhu, H. J. (H. J.). (2022) ‘Genetic and clinical factors associated with opioid response in Chinese Han patients with cancer pain: An exploratory cross sectional study’, Pain Therapy, 11(1), pp. 269–288. doi: 10.1007/s40122-022-00349-5
64. Arshad, Z., Prakash, R., Gautam, S., & Kumar, S. (2015) ‘Comparison between transdermal buprenorphine and transdermal fentanyl for postoperative pain relief after major abdominal surgeries’, Journal of Clinical Diagnostic Research, 9(12), Author code UC01–UC04. doi: 10.7860/JCDR/2015/15952.7972
65. Kumar, R., Viswanath, O., & Saadabadi, A. (2017) Buprenorphine. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from https://www.ncbi.nlm.nih.gov/books/NBK513180/
66. Nimmo, W. S., & Todd, J. G. (1985) ‘Fentanyl by constant rate IV infusion for postoperative analgesia’, British Journal of Anaesthesia, 57(3), pp. 250–254. doi: 10.1093/bja/57.3.250.
67. Yoshida, K., Nishizawa, D., Ichinomiya, T., Ichinohe, T., Hayashida, M., Fukuda, K.-i., & Ikeda, K. (2015) ‘Prediction formulas for individual opioid analgesic requirements based on genetic polymorphism analyses’, PLOS ONE, 10(1), e0116885. doi: 10.1371/journal.pone.0116885.
68. Subedi, M., Bajaj, S., Kumar, M. S., & Mayur, Y. J. (2019) ‘An overview of tramadol and its usage in pain management and future perspective’, Basic & Clinical Pharmacology & Toxicology, 111, pp. 443–451. doi: 10.1111/bcpt.13271.
69. Vidic, Z., Goricar, K., Strazisar, B., Besic, N., & Dolzan, V. J. R. (2023) ‘Association of genetic variability with acute pain, chronic pain and adverse effects after postoperative tramadol and paracetamol treatment in breast cancer’, Radiology and Oncology, 57(1), pp. 111–120. doi: 10.2478/raon-2023-0008.
70. Varghese, M., Lockey, R. F., & Asthma, C. Immunology, C. (2008) ‘Aspirin exacerbated asthma’, Allergy, Asthma & Clinical Immunology, 4, Article 1. doi: 10.1186/1710-1492-4-1.
71. Nie, X., Zhang, X., & Lu, C. Y. (2023) ‘Evidence on the impact of pharmacogenetics to treat and manage cardiovascular diseases’, in Babar, Z. U. D. (Ed.), Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy (pp. 638–685). Cham: Springer. doi: 10.1007/978 3 030 64477 2_147
72. Olivera, G., Sendra, L., Herrero, M. J., Berlanga, P., Gargallo, P., Yáñez, Y., Urtasun, A., de Mora, J. F., Castel, V., & Cañete, A. J. (2019) ‘Pharmacogenetics implementation in the clinics: Information and guidelines for germline variants’, Cancer Drug Resistance, 2(1), 53–68. doi: 10.20517/cdr.2018.25
73. Dasari, S., & Tchounwou, P. B. (2014) ‘Cisplatin in cancer therapy: Molecular mechanisms of action’, European Journal of Pharmacology, 740, 364–378. doi: 10.1016/j.ejphar.2014.07.025
74. Lanvers Kaminsky, C., Zehnhoff Dinnesen, A., Parfitt, R., & Ciarimboli, G. (2017) ‘Drug induced ototoxicity: Mechanisms, pharmacogenetics, and protective strategies’, Clinical Pharmacology & Therapeutics, 101(4), 491–500. doi: 10.1002/cpt.603
75. Hammoudeh, Z., Nikolova, D., Balabanski, L., Ivanov, S., Vazharova, R., Weidner, S., Malinov, M., Toncheva, D. J. B., & Equipment, B. (2017) ‘Screening of pharmacogenetic variants associated with drug sensitivity in patients with papillary thyroid carcinoma using next generation sequencing’, Biomedical Equipment, 31(4), 761–765. doi: 10.21608/bioeng.2017.10858.
76. Thorn, C. F., Marsh, S., Carrillo, M. W., McLeod, H. L., Klein, T. E., & Altman, R. B. (2011) ‘PharmGKB summary: Fluoropyrimidine pathways’, Pharmacogenetics and Genomics, 21(4), 237–242. doi: 10.1097/FPC.0b013e32833c6107.
77. Hamzic, S., Schärer, D., Offer, S. M., Meulendijks, D., Nakas, C., Diasio, R. B., Fontana, S., Wehrli, M., Schürch, S., & Amstutz, U. (2021) ‘Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5 fluorouracil toxicity’, British Journal of Clinical Pharmacology, 87(8), 3234–3243. doi: 10.1111/bcp.14742.
78. Božina, N., Bilić, I., Ganoci, L., Šimičević, L., Pleština, S., Lešnjaković, L., & Trkulja, V. (2022) ‘DPYD polymorphisms c.496A > G, c.2194G > A and c.85T > C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine based protocols’, British Journal of Clinical Pharmacology, 88(5), 2190–2202. doi: 10.1111/bcp.15131.
79. Herfarth, H. H., Kappelman, M. D., Long, M. D., & Isaacs, K. L. (2016) ‘Use of methotrexate in the treatment of inflammatory bowel diseases’, Inflammatory Bowel Diseases, 22(1), 224–233. doi: 10.1097/MIB.0000000000000591.
80. Koźmiński, P., Halik, P. K., Chesori, R., & Gniazdowska, E. (2020) ‘Overview of dual acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers’, International Journal of Molecular Sciences, 21(10), Article 3483. doi: 10.3390/ijms21103483.
81. Mutlak, Q. M., & Kasim, A. A. (2024) ‘Association of the rs1801133 and rs1801131 polymorphisms in the MTHFR gene and the adverse drug reaction of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients’, Pharmacia, 71, 1–8. doi: 10.3897/pharmacia.71.e113597.
82. Hao, Q., Song, Y., Fang, Q., Lin, Y., Chen, L., Wang, X., Zhang, P., Wang, Z., Gong, X., & Liu, K. J. B. S. (2023) ‘Effects of genetic polymorphisms on methotrexate levels and toxicity in Chinese patients with acute lymphoblastic leukemia’, Biomedical Sciences, 5(1), 32–38.
83. Yang, J. J., Landier, W., Yang, W., Liu, C., Hageman, L., Cheng, C., Pei, D., Chen, Y., Crews, K. R., & Kornegay, N. J. (2015) ‘Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia’, Journal of Clinical Oncology, 33(11), 1235–1242. doi: 10.1200/JCO.2014.59.4671.
84. Muhammad, M., Saifo, M., Aljamali, M., Alali, M., & Ghanem, K. M. (2024) ‘The frequency of NUDT15 rs116855232 and its impact on mercaptopurine-induced toxicity in Syrian children with acute lymphoblastic leukemia’, Frontiers in Oncology, 14, 1334846. doi: 10.3389/fonc.2024.1334846.
85. Leitsalu, L., Alavere, H., Tammesoo, M.-L., Leego, E., & Metspalu, A. J. (2015) ‘Linking a population biobank with national health registries — The Estonian experience’, Journal of Personalized Medicine, 5(2), 96–106. doi: 10.3390/jpm5020096.
86. Wahlfors, T., Simell, B., Kristiansson, K., Soini, S., Kilpi, T., Erhola, M., & Perola, M. (2022). Reaching for precision healthcare in Finland via use of genomic data. Frontiers in Genetics, 13, 877891.https://doi.org/10.3389/fgene.2022.877891
87. Turongkaravee, S., Jittikoon, J., Rochanathimoke, O., Boyd, K., Wu, O., & Chaikledkaew, U. (2021). Pharmacogenetic testing for adverse drug reaction prevention: Systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation. BMC Health Services Research, 21, Article 1–23. https://doi.org/10.1186/s12913-021-06703-6
88. Olson, M. C., Maciel, A., Gariepy, J. F., Cullors, A., Saldivar, J.-S., Taylor, D., Centeno, J., Garces, J. A., & Vaishnavi, S. J. (2017). Clinical impact of pharmacogenetic-guided treatment for patients exhibiting neuropsychiatric disorders: A randomized controlled trial. Pharmacogenetics and Genomics, 19(2), 22650. https://doi.org/10.1097/FPC.0000000000000269
89. Bank, P. C., Swen, J. J., Schaap, R. D., Klootwijk, D. B., Baak–Pablo, R., & Guchelaar, H.-J. (2019). A pilot study of the implementation of pharmacogenomic pharmacist-initiated pre-emptive testing in primary care. European Journal of Human Genetics, 27(10), 1532–1541. https://doi.org/10.1038/s41431-019-0423-6
90. Floris, M., Moschella, A., Alcalay, M., Montella, A., Tirelli, M., Fontana, L., Idda, M. L., Guarnieri, P., & Capasso, M. J. H. G. (2024). Pharmacogenetics in Italy: Current landscape and future prospects. Human Genomics, 18(1), 78. https://doi.org/10.1186/s40246-024-00422-4
91. McLellan, A. T. (2017). Substance misuse and substance use disorders: Why do they matter in healthcare? The American Journal of Psychiatry, 128, 112.https://doi.org/10.1176/appi.ajp.2017.170303.
92. Malki, M. A., & Pearson, E. R. (2020). Drug–drug–gene interactions and adverse drug reactions. Therapeutic Advances in Drug Safety, 20(3), 355–366.https://doi.org/10.1177/2042098620901496.
93. Verbelen, M., Weale, M. E., & Lewis, C. M. (2017). Cost-effectiveness of pharmacogenetic-guided treatment: Are we there yet? Pharmacogenetics and Genomics, 17(5), 395–402. https://doi.org/10.1097/FPC.0000000000000292
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Sirwan Akbar
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
